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Abstract
Background: Helicobacter pylori (H.pylori) has been implicated in the pathogenesis of
several diseases such as cardiac syndrome X (CSX), which includes chest pain, positive
exercise stress test and normal angiography. Also, elevation of homocysteine (Hcy) level is
associated with CSX, as it can severely disturb vascular endothelial function. We aimed to
elucidate whether the infection of H.pylori affect the level of Hcy in CSX.
Methods: Eighty-eight patients with CSX (32 men, 56 women; mean age: 53.8 ± 11.9) and
97 healthy controls (36 men, 61 women; mean age: 45.7 ± 7.3) were enrolled. Plasma samples
were tested for the presence of IgG antibody to H.pylori using enzyme linked immunosorbent
assay method. Hcy levels were measured enzymatically.
Results: Plasma Hcy concentration in CSX patients is higher than control group (13.1 ± 2.6
vs. 11.8 ± 2.5 mmol/L; p = 0.002). There was no significant difference between Hcy in H.pylori+
and H.pylori– individuals in CSX group (13.1 ± 2.7 vs. 12.2 ± 0.6 mmol/L; p = 0.554) and
between two groups in controls, respectively (12.1 ± 2.2 vs. 11.4 ± 2.9 mmol/L; p = 0.148).
Conclusions: Although there is Hcy level increase in H.pylori+ CSX patients and controls
comparing to H.pylori– subjects, but other factors may affect on Hcy level, too. (Cardiol J 2012;
19, 5: 466–469)
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Introduction
Cardiac syndrome X (CSX) is a clinical definition,
characterized by three main features: angina like chest
pain; ST segment depression on treadmill exercise
testing and normal coronary arteriography [1, 2]. In
about 10 to 30% patients who are referred for coro-
nary angiography, does not show vessel stenosis or
coronary spasm [3]. The pathogenesis of CSX is still
uncertain but microvascular and endothelial dysfunc-
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tion has been invoked [4]. On the other hand, plasma
homocysteine (Hcy) level, which is known to cause
endothelial dysfunction and microvascular ischemia
were higher in CSX patients [5]. Hcy is a sulphur
amino acid formed from methionine during transme-
thylation, and is either salvaged to methionine by
a folate and co-balamin-dependent re-methylation re-
action or directed toward degradation by vitamin
B6-dependent enzyme cystathionine beta-synthase [6, 7].
Also, previous studies has shown an association be-
tween viral and bacterial infections including Helico-
bacter pylori (H.pylori) and some vascular disease such
as CSX [8]. H.pylori is a spiral shaped positive gram
that cause the most common chronic bacterial infec-
tion in the world [9].
Recent data indicate a possible correlation be-
tween H.pylori infection and elevated Hcy levels
[10]. This study was aimed to examine and reveal
the possible relation between H.pylori infection and
Hcy levels in CSX.
Methods
Study population
CSX patients and apparently healthy controls
were enrolled. The CSX group consisted of 88 patients
(32 men, 56 women). Entry criteria were typical an-
gina chest pain, normal 12-lead ECGs at rest, a posi-
tive exercise ECG stress test response and normal
coronary angiogram. Non-cardiac causes of chest pain,
such as gastrointestinal and musculoskeletal disorders
were also investigated and ruled out as appropriate.
Patients with diabetes mellitus were not included,
since confirmed Hcy increase in diabetes mellitus.
The control group consisted of 97 (36 men, 61 wo-
men) apparently healthy individuals. None of the con-
trols had a previous history of chest pain or acute/
/chronic diseases. Also, none of controls were taking
cardiac or non-cardiac medication. The study was ap-
proved by the local research ethics committee and all
subjects gave written informed consent.
Study protocol
A 5-mL tri-sodium-citrated blood sample was
obtained from each subject and centrifuged at
2000 × g for 15 min. Plasma was aliquoted and
stored at –80°C until analysis. Anti-H.pylori immu-
noglobulin-G (IgG) concentration was measured
with a commercial enzyme-linked immunosorbent
assay (ELISA; Glob anti-HP/IgG, Milan, Italy) ac-
cording to the manufacturer’s instruction (sensitiv-
ity 96.5% and specificity 98.6%). The plasma Hcy
levels were measured enzymatically (Diazyme,
USA). Briefly, oxidized Hcy is first reduced to free
Hcy which then reacts with a co-substrate, S-adeno-
syl methionine (SAM), catalyzed by a Hcy S-methyl-
transferase. The co-substrate conversion product is
amplified by coupled enzymatic cycling reactions. The
total Hcy level in the sample is indirectly proportion-
al to the amount of NADH conversion to NAD+.
Statistical analysis
The data were analyzed by SPSS 16.0 software.
Age and BMI were shown as mean ± standard de-
viation (SD). The levels of homocysteine were
shown as mean ± standard error of mean (SEM)
The differences between the groups and sub-
groups were interpreted on the basis of indepen-
dent-samples t-test and for qualitative data on the
basis c2 test. A p-value less than 0.05 was consid-
ered statistically significant.
Results
The main demographic characteristics of the
two groups are presented in Table 1. The mean
body mass index was 27.2 ± 4.4 kg/m2 in CSX group
and 26.1 ± 3.2 kg/m2 in control group (p > 0.05).
Eighty two (93.2%) of CSX patients and 56
(57.7%) of controls were seropositive for H.pylori
(p = 0.001). In this study we divided the patients
in 3 groups according to the age including 25–40
years, 40–55 years and over 55 years (Table 2). In
25–40 years and 40–50 years group there were
Table 1. The main demographic characteristics
of cardiac syndrome X (CSX) and control groups.
CSX Control P
Sex (male/female) 32/56 36/61 > 0.05
Age [years] 53.8 ± 11.9 45.7 ± 7.3 0.001
Body mass index 27.2 ± 4.4 26.1 ± 3.2 > 0.05
[kg/m2]
Table 2. The prevalence of H.pylori in cardiac
syndrome X (CSX) and control groups.
Age groups [years] H.pylori+ H.pylori– P
25–40 CSX 15 (100%) 0 (0%) 0.03
Control 19 (73.1%) 7 (26.9%)
40–55 CSX 31 (96.9%) 1 (3.1%) < 0.001
Control 31 (50.8%) 30 (49.2%)
> 55 CSX 36 (87.8%) 5 (12.2%) 0.061
Control 6 (60%) 4 (40%)
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a significant difference between prevalence of anti-
H.pylori positive (H.pylori+) and anti-H.pylori nega-
tive (H.pylori–) among CSX and controls (p = 0.03
and p < 0.001, respectively). But there was no sig-
nificant difference in > 55 group (p = 0.061).
In CSX and control groups the mean level of
Hcy was 13.1 ± 2.6 and 11.8 ± 2.5 mmol/L, respec-
tively (p = 0.002). On the other hand, the mean Hcy
levels in H.pylori+ and H.pylori– individuals of CSX
group was 13.1 ± 2.7 and 12.2 ± 0.6 mmol/L, re-
spectively (p = 0.554). In control group, the mean
Hcy levels of H.pylori+ and H.pylor– individuals, was
12.1 ± 2.2 and 11.4 ± 2.9 mmol/L, respectively
(p = 0.148; Table 3). Hcy level in H.pylori+ indivi-
duals tend to increase but it is not significant in com-
parison with H.pylori–  individuals.
Discussion
Many studies showed that the elevated Hcy is
associated with endothelial dysfunction and contrib-
utes to increased risk of cardiovascular diseases
[11]. These effects are mediated by its cytotoxic ef-
fects on endothelial cells, stimulation of platelet
adhesion and/or its promotion of pro-coagulant ac-
tivity [12]. There is some evidence that thiols re-
act in the presence of NO to form S-nitrosothiols,
compounds with vasodilatory and antiplatelet ef-
fects [13]. Timurkaynak et al. [5] reported that plas-
ma Hcy level, which is known to cause endothelial
dysfunction and microvascular ischemia were high-
er in CSX patients.
In addition, Hcy metabolism involves a com-
plex interaction between folate and vitamin B12. So
chronic H.pylori infection causes decreased absorp-
tion of both folate and vitamin B12 and this condi-
tion is associated with hyperhomocysteinemia [7].
In this study because of some limitation we could
not measure folate and B12 levels in plasma.
Multiple pathophysiologic abnormalities have
been reported in patients with CSX. The most con-
vincing evidence includes generalized endothelial
dysfunction and inflammation [14]. In addition
H.pylori recently has been associated with CSX [15].
Mendall et al. in 1994, for the first time showed that
H.pylori seropositivity was twice as common in co-
ronary arteries disease patients as in control subjects
[9]. Since then, many studies have been demon-
strated an association between H.pylori infections
and some vascular diseases, such as ischemic heart
disease [16]. Chronic infection may be accompanied
by persistently increased production of inflamma-
tory metabolites [8]. H.pylori produces some anti-
genic substances, including heat shock protein, ure-
ase, and lipopolysaccharide, all of which can be
taken up and processed by lamina properia mac-
rophages and active T-cells and cause increased
production of inflammatory cytokines such as inter-
leukine-1 (IL-1), IL-6, tumor necrosis factor alpha
(TNFa), and most important IL-8. These agents
may affect vessel motility and induce endothelial
dysfunction and microvascular hyperconstriction
[15]. On the other hand, Elizade et al. in 1997
showed that H.pylori infection induces an increase
in the flux of leukocytes and in the appearance of
platelet and leukocyte-platelet aggregates in gas-
tric venules in an animal model, so platelet activa-
tion  and aggregation contribute to the associated
microvascular dysfunction and inflammatory cell
recruitment [17].
The main finding of the present study is that
patients with CSX showed increased Hcy levels as
compared to normal controls. The frequency of
H.pylori infection was also increased in patients with
CSX, and the presence of H.pylori infection did not
affect the Hcy level significantly.
Because there is no consistent evidence, the
hypothesis that H.pylori causes increased Hcy le-
vel in patients with CSX was still controversial. Re-
cent studies reported no significant difference in
blood Hcy level in H.pylori+ and H.pylori– individu-
als [18]. Our analysis showed the similar results
indicating that there is no link from H.pylori infec-
tion to increased Hcy levels in CSX patients. We
suggest that the postulated link between H.pylori
and CSX [19], if it is actually exists, is unlikely to
be mediated through elevated Hcy levels.
Conclusions
Although there is an increase in Hcy level in
H.pylori+ in CSX and controls comparing to H.pylori–
subjects, but other factors may affect on Hcy level.
Conflict of interest: none declared
Table 3. Plasma homocysteine level in cardiac
syndrome X (CSX) and control groups.
H. pylori+ H. pylori– P
Control [mmol/L] 12.1 ± 2.2 11.4 ± 2.8 0.148
CSX [mmol/L] 13.1 ± 2.7 12.2 ± 0.6 0.554
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